Barth syndrome is an ultra-rare mitochondrial disorder caused by pathogenic variants in TAFAZZIN (formerly TAZ). It is X-linked inherited and primarily affects males. Tafazzin deficiency alters mitochondrial cardiolipin and impairs energy function, particularly in the heart, skeletal muscle, and neutrophils.
Barth syndrome
The TAFAZZIN gene, located at Xq28, encodes tafazzin, a phospholipid transacylase associated with the inner mitochondrial membrane. This protein remodels the fatty acid chains of newly synthesized cardiolipin and promotes the formation of mature species, mainly tetralinoleoyl-cardiolipin. Cardiolipin contributes to maintaining mitochondrial crista organization, the stability of respiratory chain complexes, and efficient oxidative phosphorylation.
Pathogenic variants reduce or eliminate tafazzin activity, leading to decreased mature cardiolipin and accumulation of monolysocardiolipin. This alteration disorganizes the mitochondrial membrane and affects energy production, the response to metabolic stress, and the function of different tissues. The syndrome follows an X-linked inheritance pattern: hemizygous males are typically affected, and heterozygous females are usually asymptomatic, although exceptional cases related to unfavorable X chromosome inactivation or chromosomal abnormalities have been described. The estimated prevalence is approximately one in every million males, with about 230-250 patients identified worldwide, although underdiagnosis likely exists.
Symptoms
The disease usually manifests during the fetal, neonatal, or early childhood period. Cardiomyopathy usually appears before the age of five and is usually dilated, with or without endocardial fibroelastosis or left ventricular noncompaction; less commonly it is hypertrophic. It can cause difficulty breathing, feeding problems, poor weight gain, heart failure, arrhythmias, and sudden death.
Neutropenia can be persistent, cyclic, or intermittent and increases the risk of bacterial infections, aphthous ulcers, pneumonia, and sepsis. Hypotonia, proximal muscle weakness, motor delay, fatigue, and exercise intolerance are also frequent. Growth retardation before puberty, feeding difficulties, hypoglycemia, and, occasionally, lactic acidosis or learning disabilities may appear.
Disease management
There is no curative treatment. Management requires multidisciplinary follow-up, with periodic cardiological monitoring by electrocardiogram, Holter, and echocardiography, in addition to the usual treatment for heart failure and arrhythmias. Some patients may require an implantable defibrillator or a heart transplant.
Prolonged fasting and dehydration should be avoided, ensuring adequate glucose intake during illnesses or medical procedures. Physical therapy, adapted physical activity, and nutritional support help preserve function and growth.
Genes analyzed
Bibliography
Ferreira C, Pierre G, Thompson R, Vernon H. Barth Syndrome. GeneReviews®. Updated: January 8, 2026.
Orphanet. Barth syndrome. ORPHA:111.
Taylor C, Rao ES, Pierre G, et al. Clinical presentation and natural history of Barth Syndrome: an overview. J Inherit Metab Dis. 2022;45(1):7-16.
Miller PC, Ren M, Schlame M, Toth MJ, Phoon CKL. A Bayesian Analysis to Determine the Prevalence of Barth Syndrome in the Pediatric Population. J Pediatr. 2020;217:139-144.
Sergi CM. Barth Syndrome: TAFAZZIN Gene, Cardiologic Aspects, and Mitochondrial Studies-A Comprehensive Narrative Review. Genes (Basel). 2025;16(4):465.
